Literature DB >> 28127624

Oxycodone self-administration in male and female rats.

Maria Mavrikaki1, Marco Pravetoni2, Sarah Page3, David Potter3, Elena Chartoff3.   

Abstract

RATIONALE: Oxycodone is one of the most widely prescribed painkillers in the USA. However, its use is complicated by high abuse potential. As sex differences have been described in drug addiction, the present study tested for sex differences in intravenous oxycodone self-administration in rats.
METHODS: Male and female Sprague-Dawley rats were implanted with jugular vein catheters and trained to self-administer oxycodone (0.03 mg/kg/infusion) under fixed ratio 1 (FR1), FR2, and FR5 schedules of reinforcement followed by a dose-response study to assess sensitivity to the reinforcing effects of oxycodone. In separate rats, sucrose pellet self-administration was assessed under an FR1 schedule to determine whether sex differences in oxycodone self-administration could be generalized across reinforcers. In separate rats, oxycodone distribution to plasma and brain was measured after intravenous drug delivery.
RESULTS: In the first 3 trials under an FR1 schedule of reinforcement, male rats self-administered more oxycodone than females. In contrast, females self-administered more sucrose pellets. Under FR2 and FR5 schedules, no significant sex differences in oxycodone intake were observed, although female rats had significantly more inactive lever presses. Male and female rats showed similar inverted U-shaped dose-effect functions, with females tending to self-administer more oxycodone than males at higher doses. No significant sex differences were observed in plasma or brain oxycodone levels, suggesting that sex differences in oxycodone self-administration behavior were not due to pharmacokinetics.
CONCLUSION: Our results suggest subtle sex differences in oxycodone self-administration, which may influence the abuse liability of oxycodone and have ramifications for prescription opioid addiction treatment.

Entities:  

Keywords:  Motivation; Oxycodone; Self-administration; Sex differences; Sucrose reward

Mesh:

Substances:

Year:  2017        PMID: 28127624      PMCID: PMC7250466          DOI: 10.1007/s00213-017-4536-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  Gender differences in the intravenous self-administration of mu opiate agonists.

Authors:  Theodore J Cicero; Shawn C Aylward; Edward R Meyer
Journal:  Pharmacol Biochem Behav       Date:  2003-02       Impact factor: 3.533

Review 2.  Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review.

Authors:  Lin Lu; Jack D Shepard; F Scott Hall; Yavin Shaham
Journal:  Neurosci Biobehav Rev       Date:  2003-08       Impact factor: 8.989

3.  Compulsive-like responding for opioid analgesics in rats with extended access.

Authors:  Carrie L Wade; Leandro F Vendruscolo; Joel E Schlosburg; Daniel O Hernandez; George F Koob
Journal:  Neuropsychopharmacology       Date:  2014-07-25       Impact factor: 7.853

4.  Sex differences in responsiveness to the prescription opioid oxycodone in mice.

Authors:  Devon Collins; Brian Reed; Yong Zhang; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2016-06-15       Impact factor: 3.533

Review 5.  Translational Studies of Sex Differences in Sensitivity to Opioid Addiction.

Authors:  Elena H Chartoff; R Kathryn McHugh
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

6.  Intravenous cocaine and heroin self-administration in rats selectively bred for differential saccharin intake: phenotype and sex differences.

Authors:  Marilyn E Carroll; Andrew D Morgan; Wendy J Lynch; Una C Campbell; Nancy K Dess
Journal:  Psychopharmacology (Berl)       Date:  2002-03-27       Impact factor: 4.530

7.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

8.  Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment.

Authors:  Carlos A Hernandez-Avila; Bruce J Rounsaville; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2004-06-11       Impact factor: 4.492

9.  Gender differences in a clinical trial for prescription opioid dependence.

Authors:  R Kathryn McHugh; Elise E Devito; Dorian Dodd; Kathleen M Carroll; Jennifer Sharpe Potter; Shelly F Greenfield; Hilary Smith Connery; Roger D Weiss
Journal:  J Subst Abuse Treat       Date:  2013-01-11

10.  Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys.

Authors:  Patrick M Beardsley; Mario D Aceto; Charles D Cook; Edward R Bowman; Jennifer L Newman; Louis S Harris
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

View more
  28 in total

Review 1.  Epigenetic Mechanisms of Opioid Addiction.

Authors:  Caleb J Browne; Arthur Godino; Marine Salery; Eric J Nestler
Journal:  Biol Psychiatry       Date:  2019-07-08       Impact factor: 13.382

2.  Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference.

Authors:  James D Ryan; Yan Zhou; Natalina H Contoreggi; Farah K Bshesh; Jason D Gray; Joshua F Kogan; Konrad T Ben; Bruce S McEwen; Mary Jeanne Kreek; Teresa A Milner
Journal:  Neuroscience       Date:  2018-10-11       Impact factor: 3.590

3.  Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats.

Authors:  E Andrew Townsend; S Stevens Negus; S Barak Caine; Morgane Thomsen; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2019-02-28       Impact factor: 7.853

4.  Escalated Oxycodone Self-Administration Causes Differential Striatal mRNA Expression of FGFs and IEGs Following Abstinence-Associated Incubation of Oxycodone Craving.

Authors:  Christopher A Blackwood; Michael Leary; Aaron Salisbury; Michael T McCoy; Jean Lud Cadet
Journal:  Neuroscience       Date:  2019-07-24       Impact factor: 3.590

5.  Oxycodone self-administration during pregnancy disrupts the maternal-infant dyad and decreases midbrain OPRM1 expression during early postnatal development in rats.

Authors:  Fair M Vassoler; Michelle L Oranges; Anika M Toorie; Elizabeth M Byrnes
Journal:  Pharmacol Biochem Behav       Date:  2018-07-26       Impact factor: 3.533

6.  Discrimination learning in oxycodone-treated nonhuman primates.

Authors:  Sarah L Withey; Rachel J Doyle; Erica N Porter; Jack Bergman; Brian D Kangas
Journal:  Drug Alcohol Depend       Date:  2019-11-27       Impact factor: 4.492

7.  Δ9-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions.

Authors:  Jacques D Nguyen; Yanabel Grant; Kevin M Creehan; Candy S Hwang; Sophia A Vandewater; Kim D Janda; Maury Cole; Michael A Taffe
Journal:  Neuropharmacology       Date:  2019-04-11       Impact factor: 5.250

8.  Repeated blast model of mild traumatic brain injury alters oxycodone self-administration and drug seeking.

Authors:  Natalie N Nawarawong; Megan Slaker; Matt Muelbl; Alok S Shah; Rachel Chiariello; Lindsay D Nelson; Matthew D Budde; Brian D Stemper; Christopher M Olsen
Journal:  Eur J Neurosci       Date:  2018-12-14       Impact factor: 3.386

9.  Lasting effects of repeated ∆9 -tetrahydrocannabinol vapour inhalation during adolescence in male and female rats.

Authors:  Jacques D Nguyen; Kevin M Creehan; Tony M Kerr; Michael A Taffe
Journal:  Br J Pharmacol       Date:  2019-10-31       Impact factor: 8.739

10.  Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats.

Authors:  Adam Kimbrough; Jenni Kononoff; Sierra Simpson; Marsida Kallupi; Sharona Sedighim; Kenia Palomino; Dana Conlisk; Jeremiah D Momper; Giordano de Guglielmo; Olivier George
Journal:  Psychopharmacology (Berl)       Date:  2020-02-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.